Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Experimental Pharmacology and Drug Discovery

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1601873

Piperine Protects Against Cerebral Ischemic Injury by Regulating the Caspase-1-Mediated Pyroptosis Pathway

Provisionally accepted
Jiayuan  LuJiayuan LuXinwen  DaiXinwen DaiSiyu  XiSiyu XiBo  WangBo WangPeng  ZhangPeng ZhangXueyan  FuXueyan FuJuan  LiuJuan LiuYiwei  ZHangYiwei ZHang*
  • Ningxia Medical University, Yinchuan, China

The final, formatted version of the article will be published soon.

Background: Ischemic stroke (IS) is a prevalent form of stroke and marked by high rates of morbidity, disability, and mortality. Piperine (Pip) is a bioactive dietary phytochemical known for its pharmacological properties, including anti-inflammatory effects. This study aims to investigate whether Pip attenuates cerebral ischemic injury by regulating the Caspase-1-mediated pyroptosis pathway. Methods: For the in vivo simulation of cerebral ischemia, the rat permanent middle cerebral artery occlusion (pMCAO) model was utilized. For the in vitro simulation, the BV-2 cells were subjected to oxygen-glucose deprivation (OGD). The recovery of neurological function in rats was assessed through multiple behavioral tests. Pathological changes in cerebral ischemic injury were observed using TTC staining, HE staining, and transmission electron microscopy. In in vivo and in vitro experiments, the potential protective mechanism of Pip in alleviating cerebral ischemic injury. Results: In the in vivo experiments, compared with the Sham group, the Model group exhibited significant neurological damage, increased infarct volume, brain tissue edema, and elevated protein and mRNA expression levels of pyroptosis-associated factors. By contrast, the Pip group demonstrated notable improvements in behavioral function, brain tissue morphology, and the expression levels of pyroptosis-related factors compared with the Model group. In the in vitro experiments, the protein and mRNA expression of pyroptosis-associated factors in the OGD group were significantly upregulated compared with that in the Con group. However, the expression of these factors in the OGD+Pip group was markedly reduced compared with that in the OGD group.Furthermore, when cells were treated with the Caspase-1 inhibitor Ac-YVAD-cmk, the results revealed a significant decrease in the protein expression of Caspase-1 and its downstream factors, GSDMD-N and IL-1β, compared with that in the OGD group.Notably, the protein expression of GSDMD-N and IL-1β in the Pip+Ac-YVAD-cmk group was significantly higher than in the Pip group, which suggests that the inhibition of Caspase-1 attenuated the suppressive effect of Pip on GSDMD-N and IL-1β expression. Conclusions: Pip exerts neuroprotective effects by modulating the Caspase-1-mediated pyroptosis pathway, which inhibits neuronal damage in the pMCAO model. These findings highlight the therapeutic potential of Pip in mitigating cerebral ischemic injury.

Keywords: natural product, Cerebral ischemic injury, neuroprotective, pyroptosis, caspase-1

Received: 28 Mar 2025; Accepted: 14 Jul 2025.

Copyright: © 2025 Lu, Dai, Xi, Wang, Zhang, Fu, Liu and ZHang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yiwei ZHang, Ningxia Medical University, Yinchuan, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.